WSJ Report Indicates Some At DEA Dubious About Cannabis Rescheduling

1w
1m read
Summary

Read more Report: DEA Dubious About Cannabis Rescheduling Schedule III would also significantly expand the research opportunities for cannabis, cannabis products, and cannabinoids in general. HHS made its rescheduling recommendation last August following a months-long review of the available cannabis research and ongoing legalization experiments — but, according to the report, some DEA officials have contested the accuracy of the HHS findings. The agency was also sued in 2020 by cannabis researchers who said officials were purposefully failing to issue cultivation licenses for research-grade cannabis. DEA has historically slow-walked anything resembling potential cannabis reforms and was accused in 2022 of delaying the application process for bulk manufacturing cannabinoid-based pharmaceuticals.

Article Preview

This can’t come as too much of a surprise for anyone.. can it?

Via Ganjapreneur

Some officials with the Drug Enforcement Administration (DEA) are dubious about the U.S. Department of Health and Human Services’ (HHS) recommendation that cannabis be moved from Schedule I to Schedule III under the Controlled Substances Act (CSA), the Wall Street Journal reports.

HHS made its rescheduling recommendation last...

Read the full article @ Cannabis Law Report